Introduction
Lipoprotein lipase (LPL'; triacylglycerolprotein acylhydrolase, EC 3.1.1.34) is a major enzyme in lipid transport and lipoprotein metabolism. It is located on the capillary endothelium where it generates free fatty acids through the hydrolysis of the triacylglyceride core of circulating chylomicrons and VLDL. This process initiates the conversion of these lipoproteins to their remnant particles and also modulates the levels and lipid composition of high density lipoproteins.
Genetic deficiencies of LPL are uncommon, occurring at a carrier frequency of 1/500 except in certain areas of Quebec where a founder effect has increased the frequency to 1/40 (1) . Affected persons typically present in childhood with acute pancreatitis, lipaemia retinalis, and eruptive xanthoma, together with laboratory findings of chylomicronemia (2) .
Cloning of the LPL cDNA (3) established the amino acid sequence and yielded a total of 448 residues for the mature protein. Subsequent structural studies on the LPL gene identified 10 exons spanning 30 kb (4, 5) on the short arm ofchromosome 8 (6) . This has facilitated a search for gene mutations underlying LPL deficiency and several have been characterized. These include, two gene rearrangements comprising a 2-kb direct tandem duplication of the major portion of exon 6 and its 3' flanking intron (7) , and a 6-kb intragenic deletion of exons 3, 4, and 5 with breakpoints in introns 2 and 5 (8) . A missense mutation has been identified in exon 4 at residue 142 (Gly --Glu) (9) , while four other mutations are located in exon 5 and occur at amino acid positions 157 (Pro -Arg) (Kastelein, J. J. P., T. Bruin, M. V. Monsalve et al., manuscript in preparation), 176 (Ala -* Thr) (10), 188 (Gly -o Glu) (11, 12) , and 207 (Pro leu) (Ma, Y., H. E. Henderson, P. Julien et al., manuscript submitted). A further single base transition has resulted in the introduction of a termination codon at position 106 in exon 3 (13). A frameshift insertion of 5 bp has also been found in exon 3 , which results in the production ofa truncated LPL species through the generation of a premature termination codon within exon 4 (14) . The residue 188 mutation has proved to be common and accounts for -25% of all the mutant alleles in a large cohort of patients of widely differing ancestries (12) .
There is considerable homology between LPL of different species (15, 16) . One of the longest conserved regions showing complete residue identity between man, cow, mouse, and guinea pig LPL spans residues 178-2 10 of human LPL and is encoded by exon 5 (17) . In this manuscript we describe a further missense mutation in this region which results in the substitution of threonine for isoleucine at residue 194. In vitro mutagenesis studies confirmed that this amino acid substitution significantly impaired the catalytic activity ofhuman LPL and was the cause of LPL deficiency. This point mutation was found on five alleles from three unrelated persons and in association with two different LPL gene haplotypes suggesting a multicentric origin. The finding of yet another mutation in exon 5 causing LPL deficiency demonstrates the structural and functional significance of residues encoded by this exon.
This patient presented at the age of4 yr with a history ofhepatosplenomegaly and abdominal pain. Plasma lipid analysis revealed chylomicronemia with triglyceride levels in excess of 30 mmol/liter. LPL deficiency was previously established by demonstrating an absence of LPL activity in post heparin plasma using a radiolabeled triolein-triton X 100 emulsion. Plasma apo CII activator activity was observed to be normal as was the position and intensity ofthe apo CII spot on two-dimensional chromatography. Fasting lipid profiles were determined as described previously (8) . Fasting blood samples were also collected for DNA analysis from 50 unrelated normolipidaemic South Africans of Dutch descent.
Lipoprotein lipase activity and mass. Blood samples were collected from all family members and controls after an overnight fast. Postheparin plasma was obtained from blood taken 10' after an intravenous bolus of heparin administered at 60 U/kg body mass. Protease inhibitors were added to give concentrations of 10 mg/ml for leupeptin and 25 IU/ml for trasylol. Aliquots were either assayed immediately or snap frozen in liquid nitrogen and stored at -70°.
LPL activity was assayed using a radiolabeled triacylglycerol-phosphatidylcholine emulsion as previously described (18); results are expressed as nmol free fatty acid (FFA)/min/ml in post heparin plasma and nmol FFA/min/dish in the COS-I cell medium and homogenates. LPL mass was measured by ELISA using the monoclonal antibody 5D2 in a sandwich assay which detects the homodimer form of LPL (19) ; results are expressed as ng/dish. DNA analysis. Genomic DNA was isolated from leucocytes in EDTA-treated blood as described previously (20). The entire coding sequence of LPL is covered by exons 1-9 except for the last base ofthe termination codon which is coded by exon 10. The former exons were amplified by PCR using flanking, intronic sequence oligonucleotides and sequenced directly as previously described (1-2), while the first 160 bp of exon 10 were amplified using the 5' flanking intron primer 5'-CCCTTTTTCCTGTGCTTTTTC-3' and an exon 10 primer 5'-AGTGCTTGAGACTGTCTCCTAA-3' complimentary to bases 1756-1776 of the published LPL cDNA sequence (3). This PCR product was cloned into pUC vectors and sequenced by standard protocols.
DNA haplotypes in the patients and controls were constructed from three restriction fragment length polymorphisms (RFLP) at the LPL locus (21, 22) .
LPL expression phagemids. The full length human cDNA clone used in this study, pLPL35, was a kind gift from R. Lawn (Genetech Inc., San Francisco). An LPL expression phagemid was constructed by cloning a 1.6-kb Dral/EcoRl fragment ofpLPL35 in the sense orientation into the expression vector CDM8 (23) which served as a dual function vector for both mutagenesis and expression. The 1.6-kb fragment contained the entire coding sequence ofLPL flanked by 113 bp 5' to the initiation codon and 40 bp 3' to the termination codon.
Site-directed mutagenesis. Double-stranded CDM8-LPL DNA was purified and transfected into a dut-ung-host (BW3 1 3/p3/F'). Uracilcontaining single stranded CDM8-LPL phage DNA was prepared by superinfection ofthe BW3 1 3/p3/F' host with helper phage R408 (Stratagene Inc., La Jolla, CA). Mutant oligonucleotides were synthesised on an automated DNA synthesizer (model 380A; Applied Biosystems, Inc., Foster City, CA). In vitro mutagenesis was performed using the double-primer method (24) . The newly synthesized heteroduplex DNA was transfected into a dut+ ung+ host (MC1061/p3) in which the uracil-containing wild-type target strand was degraded resulting in consequent suppression ofthe wild-type colonies. Mutant clones were identified by oligonucleotide hybridization and verified by DNA sequencing.
COS-J cell transfections. Expression phagemids were introduced into the COS cells by electroporation using a Bio-Rad Laboratories (Cambridge, MA) Gene Pulser apparatus according to the manufacturer's instructions. Cells (5 X 106), harvested at /4 confluence, were resuspended in 0.8 ml of PBS, transfected with 20 ,g ofeach phagemid by pulsing at 270 V/500 ,FD. The cells were kept on ice for 10 min and transferred to three 10-cm culture dishes containing 15 ml incubation medium supplemented with heparin at 40 M/ml. Cells were grown for 72 h and judged to be of equivalent densities in all dishes by grid counting. The medium was removed, replaced with 6 ml fresh medium containing heparin, and the cells grown for a further 12 h. The medium from each dish was cleared of free cells by centrifugation and snap frozen (-70°) in l-ml aliquots. Cell monolayers were washed with PBS, containing heparin (40 Mg/ml), and removed from the dishes by incubation for 5 min at room temperature in PBS containing 2.5 mM EDTA. Cells from each dish were washed once in PBS, split into two, and subjected to protocols for the isolation ofRNA (25) and the preparation of cell lysates for LPL mass and activity determinations (26) .
Results
The proband from kindred 1 (II. 1; Fig. 1 ) presented with the classical clinical features of LPL deficiency and was found to have markedly reduced levels of LPL activity but normal mass in post-heparin plasma (Fig. 1) . Plasma apo CII activator activity was within the normal range. Chromatography of the catalytically defective enzyme on a heparin-Sepharose column revealed that 67% of the immunoreactive material in postheparin 0.7 plasma eluted at 1.1 M NaCl where normal LPL elutes, 30% at 0.7 M NaCl, and 2% in the void volume for a total recovery of 99%. the opposing strand and by repeat sequencing of exon 5 from several independent PCR amplifications. The base si tution does not create or destroy a restriction enzyme sit4 could not be confirmed in genomic DNA by restriction ment length analysis. The nucleotide sequence of exon and 6-9 together with the exon donor and acceptor splice was determined and found to be normal. The LPL termin. codon was established by amplifying and sequencing t splice site plus the first 160 bp of exon 10 and was found normal. RFLP analysis shows that this patient has two i LPL alleles and it has thus been assumed that the PCR pri have amplified the individual exons from both these allel Dot blot hybridization analysis. Detection of the T mutation was carried out using 20 ng ofPCR amplified ex DNA, transferred to Hybond N+ filters (Amersham C Arlington Heights, IL) and probed with [y-32P] labeled olig cleotides (17 mers) complementary to the normal or mi sequence spanning the T --C transition. The allele spa oligonucleotides used were ASO I, 5'-TCGAAGCAT GAATCC-3' (normal allele); and ASO II, 5'-TCGA CACTGGAATCC-3' (mutant allele). Filters were hybrid with the labeled oligomers, washed, and set up for autoradic phy as previously described (14). The autoradiograph ofa: containing amplified DNA from kindred 1 is shown in Fi This result confirms the sequencing data on proband II. 14 1), showing this individual to be a true homozygote for mutation and confirms carrier status for the Thr'94 mutatic both parents. By similar analysis we have probed exon 5 E from 50 unrelated normolipidemic control subjects and detected this mutation.
Mutation prevalence. To determine the prevalence of Thr'94 mutation in patients with LPL deficiency we scree DNA from 20 unrelated affected probands of differing ng nalities in whom the underlying gene mutations were known. Two additional probands were positive for this m tion by dot blot hybridization analysis and both were Sc Africans. The proband 11.4 from kindred 2 ( Fig. 1) was als Dutch extraction and was unrelated to our index patient. subject proved to be a true homozygote while the third affec individual II.5 (kindred 3) was heterozygous for this mutal (Fig. 3) . To validate the presence ofthe 836 T -. C transitio these two additional subjects, we determined the exon 5 sequence in DNA from several independent PCR amplifications and found the expected transitions. The remainder ofthe LPL coding sequence in these two subjects was determined by PCR It amplification and sequencing as described for proband 11.1 ( Fig. 1 ) and found to be normal.
Mutagenesis. To establish whether the substitution ofthreonine for isoleucine at amino acid position 194 destroyed the catalytic activity of LPL and was the cause ofthe enzyme deficiency in our patients, we introduced the 836 T -* C transition into the LPL expression phagemid using the mutagenic primer (Fig. 4 b) 
AG-
The LPL mass level in the medium of the cells transfected lized with the mutant cDNA was found to be 420 ng/dish (Fig. 4 b) isoleucine at residue 194 ofthe mature enzyme. This transition was detected in three unrelated persons with LPL deficiency and was confirmed as the cause oftheir enzyme abnormality by in vitro mutagenesis studies in COS-1 cells. Transfection with an LPL cDNA incorporating this mutation resulted in the synthesis and secretion of a catalytically defective LPL protein. This is the sixth missense mutation to be described to cause LPL deficiency (Fig. 6 ). All these mutations occur within a highly conserved segment, spanning residues 117-232 encoded by exons 4 and 5 and which shows significant homology with human pancreatic lipase (hPL) and human hepatic lipase (hHL) (16) . The localization of the mutations to this region of the protein is unlikely to be due to an ascertainment bias through preferential sequence analysis of exon 5 in affected patients, as these mutations together account for a significant majority of the mutant alleles in a cohort of 75 LPL-deficient patients, of various ancestries, examined in this laboratory. Rather, this observation supports earlier data alluding to the structural and functional significance of the residues encoded by exons 4 and 5 (17). These residues include those comprising the proposed interfacial binding site and the active site serine at position 132 (15, 27).
The pronounced homology between the known amino acid sequences of human LPL, HL, and PL permits an alignment with few ambiguities (16, 5) and suggests that their three-dimensional structures are likely to be similar. The known threedimensional structure ofPL (27) was used to examine the possible effect of the Thrl94 substitution on the structure and function of LPL. The active site of PL contains an Asp(l 76) . His(263) . . . Ser( 152) triad similar to that found in trypsinlike proteases (27). Isoleucine at position 194 of LPL corresponds to phenylalanine 215 (Phe215) of PL which is located near the essential histidine of the Asp . . . His . . . Ser catalytic triad of PL. Phe215 is one of the hydrophobic residues surrounding the active site (Fig. 7) and is likely to be in hydrophobic interaction with the alkyl side chains ofthe triglyceride substrate. Further, the side chain ofPhe215 is in van der Waals contact with Tyrl 14, Alal71, and Prol80 which are all conserved in LPL. An isoleucine side chain can be easily accommodated in the same environment and Ile 194 can be assumed to occupy a very similar position in lipoprotein lipase.
The replacement ofisoleucine by the smaller and more hydrophilic threonine in the inactive mutant could affect the enzymatic activity in various ways. The smaller size is unlikely to have a dramatic effect and indeed HL has a valine in the equivalent position. A substitution of valine for isoleucine in LPL at position 194 would not be expected to alter the catalytic activity of the enzyme. The hydrophilic hydroxyl group of threonine, however, might disrupt the hydrophobic surface that is needed for a favorable interaction with the alkyl chains oftriacylglyceride substrates. Alternatively, it could lead to a change in the hydration of the active site region with effects on the catalytic mechanism and/or the interaction with substrate. Assessment ofthese suggested mechanisms awaits the elucidation of the three-dimensional structure of LPL.
We have clearly shown through in vitro mutagenesis studies that the Thr'94 substitution impairs the catalytic activity of LPL towards long chain triacylglycerides, but its effects on the other functional properties and molecular interactions of the mutant enzyme are unclear. The heparin binding site, however, appears to be unaffected as the mutant enzyme binds to the luminal surface of the capillary endothelium. This was revealed by the very low levels of LPL mass detected in pre-heparin plasma from proband II.1 ( Fig. 1) and the substantial increase observed in the plasma after heparin infusion (Fig. 1) . Further, 97% of the incremental mass in post-heparin plasma bound to a heparin-Sepharose affinity column and the major fraction ofthis material (67%) eluted at the same sodium chloride concentration as normal LPL.
We have not established whether the relative decrease in the concentration of the mutant LPL protein in the medium from the transfected COS cells is due to impaired secretion or accelerated degradation. However, it would appear that LPL mRNA levels are similar in both transfected cell cultures, indicating that levels of phagemid expression are similar and cannot account for the observed differences.
The association ofthe 836 T --C transition with two different RFLP haplotypes in our patients was unexpected. Studies of human genetic diseases have revealed that specific mutations are usually associated with only one haplotype and probably represent single ancestral events (28, 29) . Less commonly however, mutations have been found to segregate with different haplotypes and are likely to be either very old or have occurred more than once on different chromosomal backgrounds (30, 31) . Many of these mutations have occurred at CpG dimers, which may be hot spots for mutation and may account for the recurrent events at these sites. The haplotypes associated with the Thr'" mutation differ at two of the three polymorphic restriction sites and it is unlikely, therefore, that these changes have recently occurred through random mutations af- fecting these specific cutting sites. Further, the possibility that the multiplicity of haplotypes is indicative of a very old mutational event is slight, as the mutation was not found in a large cohort of LPL-deficient patients of different nationalities. These data are more consistent with the occurrence of two separate ancestral events on different chromosomal backgrounds and suggest a multicentric origin for this mutation. Knowledge of DNA sequence alterations in the LPL gene and the synthesis of mutation-specific oligonucleotides simplifies the unequivocal diagnosis of carriers in affected families. The probands examined in this study come from extensive kindreds and it will now be possible to collect blood from large numbers of family relatives and identify carriers in significant numbers to examine the relationship between heterozygosity for LPL deficiency and lipoprotein abnormalities. In addition, an association between the heterozygous state and the presence of premature coronary atherosclerosis can now be explored (19) .
